Hepatic Impairment Pipeline Analysis Report 2026

Report Coverage

The Hepatic Impairment Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hepatic impairment therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hepatic impairment. The hepatic impairment report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hepatic impairment pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hepatic impairment treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hepatic impairment.

Read more about this report - Request a Free Sample

Hepatic Impairment Pipeline Outlook

Hepatic impairment encompasses chronic liver diseases where conventional management includes ursodeoxycholic acid, lifestyle measures, and symptom control, but significant unmet needs remain.

Hepatic impairment treatment is increasingly focused on advancing targeted therapies that address underlying pathology and key biochemical markers. A key milestone occurred in August 2024, when the FDA granted accelerated approval to Livdelzi (seladelpar) for primary biliary cholangitis (PBC), offering a novel option for patients unresponsive to standard therapy and reflecting growing innovation in liver disease treatment.

Hepatic Impairment Epidemiology

Hepatic impairment broadly reflects the clinical consequences of chronic liver disease, which affects a significant share of the global population. In 2021, approximately 1.70 billion people worldwide were living with cirrhosis and other chronic liver conditions, underscoring a substantial public health burden. Globally, the prevalence of advanced liver fibrosis and cirrhosis is estimated at 3.3% and 1.3%, respectively. Steatotic liver disease, a major contributor to hepatic dysfunction, has a pooled prevalence of nearly 37.5% among adults, highlighting the extensive scale of liver impairment across populations.

Hepatic Impairment – Pipeline Therapeutic Assessment

Hepatic Impairment Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total hepatic impairment clinical trials. Phase I dominates with 98% of ichthyosis clinical trials, highlighting the strong focus on early-stage clinical evaluation and safety assessment of therapies in this patient population.

Hepatic Impairment Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the hepatic impairment pipeline analysis include monoclonal antibodies, small-molecule drugs, and gene therapies. The hepatic impairment report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hepatic impairment. In March 2024, the FDA granted accelerated approval to Rezdiffra (resmetirom) for adults with noncirrhotic metabolic dysfunction associated steatohepatitis (MASH/NASH) and moderate to advanced fibrosis. The therapy, a thyroid hormone receptor-β agonist, targets liver fat reduction and fibrosis improvement. This approval marks the first disease specific option for progressive NASH patients, addressing a critical unmet need in hepatic impairment management.

Hepatic Impairment Clinical Trials – Key Players

The EMR report for the hepatic impairment pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hepatic impairment therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hepatic impairment clinical trials:

• AbbVie
• Guangdong Raynovent Biotech Co., Ltd
• Alumis Inc
• Merck Sharp & Dohme LLC
• Vir Biotechnology, Inc.
• Pfizer
• Boehringer Ingelheim
• Celgene
• Bristol-Myers Squibb
• Eli Lilly and Company
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Taiho Oncology, Inc.

Hepatic Impairment – Emerging Drugs Profile

Key Questions Answered in the Hepatic Impairment Pipeline Insight Report

• Which companies/institutions are leading the hepatic impairment drug development?
• Which company is leading the hepatic impairment pipeline development activities?
• What is the current hepatic impairment commercial assessment?
• What are the opportunities and challenges present in the hepatic impairment pipeline landscape?
• What is the efficacy and safety profile of hepatic impairment pipeline drugs?
• Which company is conducting major trials for hepatic impairment drugs?
• Which companies/institutions are involved in hepatic impairment collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Hepatic Impairment?

Reasons To Buy This Report

The Hepatic Impairment Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hepatic impairment. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hepatic impairment collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Hepatic Disease Treatment Market

Hepatic Encephalopathy Treatment Market

Hepatic Tumor Pipeline Analysis Report